About this trial
The goal of this clinical trial is to learn whether early microincision vitrectomy surgery (MIVS) can improve retinal neovascularization outcomes compared to standard pan-retinal photocoagulation (PRP) in patients with early proliferative diabetic retinopathy (PDR). It will also evaluate the safety and functional outcomes of early surgical intervention in this population.
The main questions it aims to answer are:
Does early MIVS increase the proportion of eyes achieving complete regression of retinal neovascularization at 12 months? Does early MIVS improve visual and functional outcomes, including visual acuity and visual field, compared to PRP? Researchers will compare early MIVS combined with peripheral scatter photocoagulation to standard PRP to determine whether early surgical intervention leads to better regression of neovascularization and improved clinical outcomes.
Participants will:
Receive either MIVS with peripheral photocoagulation or standard PRP Undergo retinal imaging assessments including fundus fluorescein angiography (FFA) or optical coherence tomography angiography (OCTA) Complete follow-up visits over 12 months, including visual acuity testing, visual field testing, and optical coherence tomography (OCT) imaging Be monitored for the occurrence of vitreous hemorrhage and other clinical outcomes
Eligibility criteria
Qualifiers
Age 18 years or older.
Disqualifiers
Prior panretinal photocoagulation, macular photocoagulation, or vitrectomy in the study eye.
Trial design
Treatments tested in this trial
- Microincision Vitrectomy Surgery
- Panretinal Photocoagulation
Treatment groups
Sponsors and collaborators
Xiamen Ophthalmology Center Affiliated to Xiamen University
Lead sponsor
Jiangsu Provincial People's Hospital
Collaborator
Peking University People's Hospital
Collaborator
Henan Provincial People's Hospital
Collaborator
Nanjing Medical University
Collaborator
The First Affiliated Hospital of Dalian Medical University
Collaborator